Skip to content

Clinical study of intratympanic corticosteroid treatment for sudden hearing loss

Clinical study of intratympanic corticosteroid treatment for sudden hearing loss

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOD-16009655
Enrollment
Unknown
Registered
2016-10-27
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden hearing loss

Interventions

Group A(standard treatment):Dexamethasone 10mg intravenous drip once a day for 5 days
Group B:Dexamethasone 5mg intratympanic once a day for 5 days
Group C: dexamethasone 5mg,intratympanic , qod * 5
group D:Dexamethasone 10mg,intratympanic, once a day for 5 consecutive days
Group E:Dexamethasone, 10mg intratympanic, qod*5
Group F:Methylprednisolone 20mg, intratympanic injection, qd*5
Group G:methylprednisolone20mg,intratympanic, qod*5
Group G:methylprednisolone40mg,intratympanic, qd*5
Group I :methylprednisolone40mg,intratympanic, qod*5

Sponsors

Xinhua Hospital, Medicine School of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients diagnosed as sudden hearing loss aged 18-80 years old; 2. No contraindication of intratympanic injection of glucocorticoid; 3. no tympanic perforation.

Exclusion criteria

Exclusion criteria: 1. children; 2. Combined mental and psychological diseases; 3. Patients with a clear cause of the disease; 4. To give up treatment or automatic discharge before the end of the trial.

Design outcomes

Primary

MeasureTime frame
cure rate;Effective rate;

Countries

China

Contacts

Public ContactMei Ling

Xinhua hospital affiliated to Medicine School of Shanghai Jiaotong University

lingmei5111@163.com+86 13761688632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026